Arrowhead Pharmaceuticals Inc (ARWR)

Debt-to-capital ratio

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Long-term debt US$ in thousands
Total stockholders’ equity US$ in thousands 160,407 271,343 364,830 446,772 377,039 398,520 453,927 452,266 372,560 408,822 436,890 445,549 454,472 461,779 493,140 494,119 500,084 244,591 226,225 201,195
Debt-to-capital ratio 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $160,407K)
= 0.00

The debt-to-capital ratio for Arrowhead Pharmaceuticals Inc. has been consistently reported as 0.00 across all quarters for the years 2022 and 2023. This indicates that the company has not used any debt to finance its operations relative to its total capital structure during these periods. A debt-to-capital ratio of 0.00 suggests that the company relies solely on equity financing or has minimal debt obligations compared to its equity. While a low or zero debt-to-capital ratio can be a positive sign of financial stability and lower risk, it's essential to consider other financial metrics and factors to gain a more comprehensive understanding of Arrowhead Pharmaceuticals' overall financial health and performance.


Peer comparison

Dec 31, 2023